Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases

被引:214
作者
Beeton, C
Pennington, MW
Wulff, H
Singh, S
Nugent, D
Crossley, G
Khaytin, I
Calabresi, PA
Chen, CY
Gutman, GA
Chandy, KG
机构
[1] Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Irvine, CA 92697 USA
[2] Bachem Biosci Inc, King Of Prussia, PA USA
[3] Univ Calif Davis, Dept Med Pharmacol & Toxicol, Davis, CA 95616 USA
[4] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA
关键词
D O I
10.1124/mol.104.008193
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The voltage-gated Kv1.3 K+ channel is a novel target for immunomodulation of autoreactive effector memory T ( T EM) cells that play a major role in the pathogenesis of autoimmune diseases. We describe the characterization of the novel peptide ShK(L5) that contains L-phosphotyrosine linked via a nine-atom hydrophilic linker to the N terminus of the ShK peptide from the sea anemone Stichodactyla helianthus. ShK(L5) is a highly specific Kv1.3 blocker that exhibits 100-fold selectivity for Kv1.3 (K-d = 69 pM) over Kv1.1 and greater than 250-fold selectivity over all other channels tested. ShK(L5) suppresses the proliferation of human and rat TEM cells and inhibits interleukin-2 production at picomolar concentrations. Naive and central memory human T cells are initially 60-fold less sensitive than T EM cells to ShK( L5) and then become resistant to the peptide during activation by up-regulating the calcium-activated K(Ca)3.1 channel. ShK(L5) does not exhibit in vitro cytotoxicity on mammalian cell lines and is negative in the Ames test. It is stable in plasma and when administered once daily by subcutaneous injection (10 mu g/kg) attains "steady state" blood levels of similar to 300 pM. This regimen does not cause cardiac toxicity assessed by continuous EKG monitoring and does not alter clinical chemistry and hematological parameters after 2-week therapy. ShK(L5) prevents and treats experimental autoimmune encephalomyelitis and suppresses delayed type hypersensitivity in rats. ShK(L5) might prove useful for therapy of autoimmune disorders.
引用
收藏
页码:1369 / 1381
页数:13
相关论文
共 68 条
[1]  
ATWAL KS, 2001, Patent No. 0140231
[2]   Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3:: Synthesis and immunosuppressive activity [J].
Baell, JB ;
Gable, RW ;
Harvey, AJ ;
Toovey, N ;
Herzog, T ;
Hänsel, W ;
Wulff, H .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (09) :2326-2336
[3]  
BAGDANY M, 2005, MOL PHARM, V67, P1
[4]   Potent Kv1.3 inhibitors from correolide - modification of the C18 position [J].
Bao, JM ;
Miao, SW ;
Kayser, F ;
Kotliar, AJ ;
Baker, RK ;
Dossa, GA ;
Felix, JP ;
Bugianesi, RM ;
Slaughter, RS ;
Kaczorowski, GJ ;
Garcia, ML ;
Ha, SN ;
Castonguay, L ;
Koo, GC ;
Shah, K ;
Springer, MS ;
Staruch, MJ ;
Parsons, WH ;
Rupprecht, KM .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (02) :447-451
[5]   Characterisation of the human voltage-gated potassium channel gene, KCNA7, a candidate gene for inherited cardiac disorders, and its exclusion as cause of progressive familial heart block I (PFHBI) [J].
Bardien-Kruger, S ;
Wulff, H ;
Arieff, Z ;
Brink, P ;
Chandy, KG ;
Corfield, V .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2002, 10 (01) :36-43
[6]   A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes [J].
Beeton, C ;
Wulff, H ;
Singh, S ;
Botsko, S ;
Crossley, G ;
Gutman, GA ;
Cahalan, MD ;
Pennington, M ;
Chandy, KG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (11) :9928-9937
[7]   Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation [J].
Beeton, C ;
Barbaria, J ;
Giraud, P ;
Devaux, J ;
Benoliel, AM ;
Gola, M ;
Sabatier, JM ;
Bernard, D ;
Crest, M ;
Béraud, E .
JOURNAL OF IMMUNOLOGY, 2001, 166 (02) :936-944
[8]   Selective blockade of T lymphocyte K+ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis [J].
Beeton, C ;
Wulff, H ;
Barbaria, J ;
Clot-Faybesse, O ;
Pennington, M ;
Bernard, D ;
Cahalan, MD ;
Chandy, KG ;
Béraud, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (24) :13942-13947
[9]   PATHOGENIC AND NONPATHOGENIC T-LYMPHOCYTES SPECIFIC FOR THE ENCEPHALITOGENIC EPITOPE OF MYELIN BASIC-PROTEIN - FUNCTIONAL-CHARACTERISTICS AND VACCINATION PROPERTIES [J].
BERAUD, E ;
BALZANO, C ;
ZAMORA, AJ ;
VARRIALE, S ;
BERNARD, D ;
BENNUN, A .
JOURNAL OF NEUROIMMUNOLOGY, 1993, 47 (01) :41-54
[10]   CD45RC isoforms define two types of CD4 memory T cells, one of which depends on persisting antigen [J].
Bunce, C ;
Bell, EB .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (04) :767-776